Skip to main content
Fig. 1 | Critical Care

Fig. 1

From: Exogenous vasopressin dose-dependently modulates gastric microcirculatory oxygenation in dogs via V1A receptor

Fig. 1

Experimental protocol. Time control treatment with application of normal saline (C) or sole V1A receptor blockade (VB). Application of vasopressin with dose escalation every 30 min in V1A receptor patent dogs (AVP) or with prior application of a V1A receptor inhibitor (AVP VB). Dose escalation of vasopressin: dose 1, 0.001 ng/kg/min; dose 2, 0.01 ng/kg/min; dose 3, 0.1 ng/kg/min; dose 4, 1 ng/kg/min. Doses 1 and 2 represent a subclinical, ultra-low dosage; doses 3 + 4 are comparable to common, clinical low dose AVP application. VB = [Pmp1, Tyr (Me)2]-Arg8-Vasopressin, 35 μg/kg in 20 ml, i.v.; ▼ = 250 mU AVP

Back to article page